Gangi A, Essner R, Giuliano A E
Division of Surgical Oncology, Department of Surgery Cedars-Sinai Medical Center, Los Angeles, CA, USA -
Q J Nucl Med Mol Imaging. 2014 Jun;58(2):95-104.
Sentinel lymph node biopsy (SLNB) is based on the hypothesis that the sentinel lymph node (SLN) reflects the lymph-node status and a negative SLN might allow complete axillary lymph node dissection (ALND) to be avoided. Past and current sentinel lymph node clinical trials for breast carcinoma and melanoma address the prognostic and therapeutic utility of SLN dissection (SLND). This technique has already become a standard of care for breast cancer patients and select patients with melanoma. However, it is still important to discuss current techniques and some controversies. This article reviews these issues as well as current guidelines for treatment and management of patients with various findings on SLNB.
前哨淋巴结活检（SLNB）基于这样一种假设，即前哨淋巴结（SLN）反映淋巴结状态，前哨淋巴结阴性可能避免进行腋窝淋巴结清扫术（ALND）。过去和当前针对乳腺癌和黑色素瘤的前哨淋巴结临床试验探讨了前哨淋巴结清扫术（SLND）的预后和治疗效用。这项技术已成为乳腺癌患者和部分黑色素瘤患者的标准治疗方法。然而，讨论当前技术和一些争议问题仍然很重要。本文回顾了这些问题以及针对前哨淋巴结活检有各种检查结果的患者的当前治疗和管理指南。
